S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Real Problem With "Made in America" Lithium (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
How to Invest in AI's Fast-Growing Market (Ad)
Okta, Inc: When Great Results Aren’t Good Enough 
How to Invest in Specialty Retail Stores
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Real Problem With "Made in America" Lithium (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
How to Invest in AI's Fast-Growing Market (Ad)
Okta, Inc: When Great Results Aren’t Good Enough 
How to Invest in Specialty Retail Stores
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Real Problem With "Made in America" Lithium (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
How to Invest in AI's Fast-Growing Market (Ad)
Okta, Inc: When Great Results Aren’t Good Enough 
How to Invest in Specialty Retail Stores
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
20 Best Healthcare Dividend Stocks to Invest in
The Real Problem With "Made in America" Lithium (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
How to Invest in AI's Fast-Growing Market (Ad)
What is the Penalty for Excess Contributions to an IRA?
Chewy.com Gets A Mouthful Of Profits: Shares Surge, More To Come
How to Invest in AI's Fast-Growing Market (Ad)
Okta, Inc: When Great Results Aren’t Good Enough 
How to Invest in Specialty Retail Stores
NASDAQ:SNSE

Sensei Biotherapeutics (SNSE) Stock Forecast, Price & News

$1.46
0.00 (0.00%)
(As of 06/1/2023 ET)
Compare
Today's Range
$1.46
$1.55
50-Day Range
$1.31
$1.81
52-Week Range
$1.28
$2.39
Volume
13,317 shs
Average Volume
20,748 shs
Market Capitalization
$45.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Sensei Biotherapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.38
Upright™ Environmental Score
News Sentiment
0.56mentions of Sensei Biotherapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.31) to ($1.56) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

1233rd out of 1,980 stocks

Pharmaceutical Preparations Industry

617th out of 978 stocks


SNSE stock logo

About Sensei Biotherapeutics (NASDAQ:SNSE) Stock

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Receive SNSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sensei Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

SNSE Stock News Headlines

The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
Citigroup Remains a Buy on Sensei Biotherapeutics (SNSE)
Sensei Biotherapeutics (NASDAQ:SNSE) Shares Down 16.6%
How to Invest in AI's Fast-Growing Market
The AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.
See More Headlines

SNSE Price History

SNSE Company Calendar

Last Earnings
3/28/2023
Today
6/02/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNSE
Fax
N/A
Employees
56
Year Founded
N/A

Profitability

Net Income
$-48,590,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.06 per share

Miscellaneous

Free Float
24,816,000
Market Cap
$45.08 million
Optionable
Not Optionable
Beta
-0.18

Key Executives

  • Mr. John K. Celebi M.B.A. (Age 50)
    MBA, Pres, CEO & Director
    Comp: $792.98k
  • Ms. Erin Colgan (Age 41)
    Chief Financial Officer
    Comp: $453.19k
  • Dr. Steven A. Fuller
    Chief Biopharmaceuticals Devel. Officer
  • Dr. Edward Van der Horst Ph.D.
    Chief Scientific Officer
  • Ms. Lora Pike
    VP of Investor Relations & Communications
  • Mr. Christopher Gerry J.D.
    VP & Gen. Counsel
  • Mr. Patrick Stephen Gallagher M.B.A.
    M.P.H., Chief Bus. Officer













SNSE Stock - Frequently Asked Questions

Should I buy or sell Sensei Biotherapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sensei Biotherapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SNSE shares.
View SNSE analyst ratings
or view top-rated stocks.

How have SNSE shares performed in 2023?

Sensei Biotherapeutics' stock was trading at $1.49 at the start of the year. Since then, SNSE stock has decreased by 2.3% and is now trading at $1.4550.
View the best growth stocks for 2023 here
.

Are investors shorting Sensei Biotherapeutics?

Sensei Biotherapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 154,800 shares, a drop of 15.5% from the April 30th total of 183,100 shares. Based on an average daily trading volume, of 79,100 shares, the short-interest ratio is currently 2.0 days. Currently, 1.0% of the shares of the company are sold short.
View Sensei Biotherapeutics' Short Interest
.

When is Sensei Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our SNSE earnings forecast
.

How were Sensei Biotherapeutics' earnings last quarter?

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) announced its earnings results on Tuesday, March, 28th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.01.

When did Sensei Biotherapeutics IPO?

(SNSE) raised $100 million in an IPO on Friday, February 5th 2021. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Citigroup, Piper Sandler, Berenberg and Oppenheimer & Co. served as the underwriters for the IPO.

What is Sensei Biotherapeutics' stock symbol?

Sensei Biotherapeutics trades on the NASDAQ under the ticker symbol "SNSE."

Who are Sensei Biotherapeutics' major shareholders?

Sensei Biotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.40%), Bank of America Corp DE (0.29%) and Two Sigma Advisers LP (0.08%). Insiders that own company stock include Apeiron Investment Group Ltd, Cambrian Biopharma Inc, James Peyer, Robert Hamilton Pierce and Thomas G Ricks.
View institutional ownership trends
.

How do I buy shares of Sensei Biotherapeutics?

Shares of SNSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sensei Biotherapeutics' stock price today?

One share of SNSE stock can currently be purchased for approximately $1.46.

How much money does Sensei Biotherapeutics make?

Sensei Biotherapeutics (NASDAQ:SNSE) has a market capitalization of $45.08 million. The company earns $-48,590,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis.

How can I contact Sensei Biotherapeutics?

Sensei Biotherapeutics' mailing address is 1405 RESEARCH BLVD SUITE 125, ROCKVILLE MD, 20850. The official website for the company is www.senseibio.com. The company can be reached via phone at 240-243-8000 or via email at ir@senseibio.com.

This page (NASDAQ:SNSE) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -